Mineralys Therapeutics, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor initially targeting uncontrolled or resistant hypertension, with potential applications in chronic kidney disease and other cardiorenal disorders. The filing covers the three months ended March 31, 2023, and was filed May 15, 2023.
The company has no approved products, has generated no product revenue, and remains dependent on financing to fund research, development, and operations.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $12.3 million | $6.8 million | +$5.5 million |
| General and administrative expense | $2.6 million | $0.8 million | +$1.9 million |
| Total operating expenses | $14.9 million | $7.6 million | +$7.4 million |
| Interest and other income, net | $2.3 million | $0 | +$2.3 million |
| Net loss | $12.6 million | $7.6 million | +$5.0 million loss |
| Basic and diluted net loss per share | $0.51 | $1.48 | Lower loss per share due primarily to increased share count |
| Net cash used in operating activities | $12.8 million | $6.6 million | +$6.2 million use |
Operating and net profit margins are not meaningful because the company has no revenue and is loss-making. Cash and cash equivalents were $138.2 million at March 31, 2023, compared with $87.7 million at December 31, 2022. Investments totaled $163.5 million, bringing cash, cash equivalents, and investments to $301.8 million.
Total assets were $306.4 million and stockholders’ equity was $295.9 million at March 31, 2023. Current liabilities were $10.6 million. The filing does not disclose outstanding debt; no material debt balance is reported in the condensed balance sheet.
Material changes versus the prior comparable period
- Research and development expense increased 81%, primarily because of a $4.0 million Mitsubishi Tanabe development milestone, higher employee compensation, increased clinical supply, manufacturing and regulatory costs, and other development spending.
- General and administrative expense increased 234%, reflecting additional personnel, public-company professional fees, administrative costs, and directors’ and officers’ insurance.
- Interest income increased to $2.3 million as cash was invested in money market funds and U.S. Treasury securities.
- Net cash used in operations nearly doubled to $12.8 million as development, personnel, professional-fee, and working-capital requirements increased.
- Investing activities used $140.3 million, principally for purchases of marketable securities following the IPO.
- Financing activities provided $203.6 million, including approximately $201.4 million of net IPO proceeds.
- All Series A and Series B preferred stock converted into common stock upon the IPO. Common shares outstanding increased to 40.9 million at March 31, 2023 from 6.4 million at December 31, 2022.
Guidance, outlook, risks, and unusual items
- In April 2023, the company initiated Advance-HTN, a Phase 2 pivotal trial expected to enroll up to approximately 300 subjects. Topline data is expected in the first half of 2024.
- Launch-HTN, a Phase 3 trial expected to enroll up to approximately 1,000 subjects, is planned for the second half of 2023, with topline data expected in mid-2025.
- An open-label extension trial and a Phase 2 chronic kidney disease trial were planned for mid-2023, with CKD topline data expected in the first half of 2024.
- Management expects research and development and general and administrative expenses, operating losses, and negative operating cash flow to increase substantially as clinical development and public-company activities expand.
- Management believes available cash, cash equivalents, and investments will fund operations for at least twelve months from the financial statement issuance date. This estimate is subject to clinical, regulatory, manufacturing, spending, and financing uncertainties.
- The company expects to require additional funding through equity, debt, collaborations, licenses, or other arrangements. No committed external source of funding exists, creating potential dilution, restrictive financing terms, or delays to development if capital is unavailable.
- The Mitsubishi Tanabe license includes up to $9.0 million of development milestones, up to $165.0 million of commercial milestones across indications, and tiered royalties ranging from the mid-single digits to 10% of net sales. A $4.0 million development milestone was accrued at March 31, 2023 and paid after quarter-end.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, manufacturing and supply-chain costs, intellectual-property obligations, dependence on lorundrostat, future financing needs, and the absence of product revenue. No material legal proceedings or material changes to previously disclosed risk factors were reported.
- Disclosure controls and procedures were assessed as effective as of March 31, 2023, with no material changes in internal control over financial reporting.
Most important facts for investors to verify
- Whether Advance-HTN and Launch-HTN begin and progress according to the disclosed timelines, including enrollment and topline-data dates.
- Clinical efficacy, safety, and regulatory feedback for lorundrostat in hypertension and chronic kidney disease.
- The pace of quarterly cash burn relative to the $301.8 million cash, cash equivalents, and investments balance.
- Timing and terms of any future equity or debt financing and the resulting dilution or restrictions.
- Future Mitsubishi Tanabe milestone obligations, royalty exposure, and license-compliance requirements.
- Whether operating expenses and losses increase as projected and whether the company ultimately generates product revenue.